دورية أكاديمية
أعرض في EDS

The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma.

التفاصيل البيبلوغرافية
العنوان: The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma.
المؤلفون: Joseph C; School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham NG7 2RD, UK., Alsaleem MA; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.; Department of Applied Medical Sciences, Unayzah Community College, Qassim University, Unayzah 56435, Saudi Arabia., Toss MS; School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham NG7 2RD, UK.; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK., Kariri YA; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.; Department of Clinical Laboratory Science, Faculty of Applied Medical Science, Shaqra University 33, Shaqra 11961, Saudi Arabia., Althobiti M; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.; Department of Clinical Laboratory Science, Faculty of Applied Medical Science, Shaqra University 33, Shaqra 11961, Saudi Arabia., Alsaeed S; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK., Aljohani AI; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK., Narasimha PL; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK., Mongan NP; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK., Green AR; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK., Rakha EA; School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham NG7 2RD, UK.; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.
المصدر: Cancers [Cancers (Basel)] 2020 Dec 30; Vol. 13 (1). Date of Electronic Publication: 2020 Dec 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: The leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) plays a role in immune response homeostasis, extracellular matrix remodelling and it is overexpressed in many high-grade cancers. This study aimed to elucidate the biological and prognostic role of LAIR-1 in invasive breast cancer (BC).
Methods: The biological and prognostic effect of LAIR-1 was evaluated at the mRNA and protein levels using well-characterised multiple BC cohorts. Related signalling pathways were evaluated using in silico differential gene expression and siRNA knockdown were used for functional analyses.
Results: High LAIR-1 expression either in mRNA or protein levels were associated with high tumour grade, poor Nottingham Prognostic Index, hormone receptor negativity, immune cell infiltrates and extracellular matrix remodelling elements. High LAIR-1 protein expression was an independent predictor of shorter BC-specific survival and distant metastasis-free survival in the entire BC cohort and human epidermal growth factor receptor 2 (HER2)+ subtype. Pathway analysis highlights LAIR-1 association with extracellular matrix remodelling-receptor interaction, and cellular proliferation. Depletion of LAIR-1 using siRNA significantly reduced cell proliferation and invasion capability in HER2+ BC cell lines.
Conclusion: High expression of LAIR-1 is associated with poor clinical outcome in BC. Association with immune cells and immune checkpoint markers warrant further studies to assess the underlying mechanistic roles.
References: Histopathology. 2017 Mar;70(4):622-631. (PMID: 27782306)
J Exp Med. 2006 Apr 17;203(4):883-95. (PMID: 16606670)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Drugs. 2020 Apr;80(6):601-607. (PMID: 32248356)
J Clin Pathol. 2012 Feb;65(2):159-63. (PMID: 22049225)
Database (Oxford). 2013 Jan 15;2013:bas060. (PMID: 23325629)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Gynecol Oncol. 2008 Aug;110(2):216-21. (PMID: 18533240)
J R Soc Interface. 2015 Feb 6;12(103):. (PMID: 25505134)
Oncoimmunology. 2012 May 1;1(3):364-365. (PMID: 22737616)
Oncoimmunology. 2020 Apr 7;9(1):1740477. (PMID: 33457088)
Adv Immunol. 1999;72:149-77. (PMID: 10361574)
N Engl J Med. 2019 Mar 7;380(10):987-988. (PMID: 30855757)
J Immunol. 1999 May 15;162(10):5800-4. (PMID: 10229813)
Exp Ther Med. 2016 Dec;12(6):3699-3705. (PMID: 28105100)
Biochem Biophys Res Commun. 2015 Mar 6;458(2):399-404. (PMID: 25660999)
Br J Cancer. 2004 Oct 18;91(8):1532-42. (PMID: 15480434)
Mod Pathol. 2005 Oct;18(10):1295-304. (PMID: 15976813)
Mol Immunol. 2011 Oct;49(1-2):402-6. (PMID: 21955987)
Surg Oncol Clin N Am. 2018 Jan;27(1):95-120. (PMID: 29132568)
Haematologica. 2014 May;99(5):881-7. (PMID: 24415628)
Breast Cancer Res Treat. 2010 Jan;119(2):283-93. (PMID: 19238537)
Oncotarget. 2017 May 9;8(19):31347-31354. (PMID: 28430626)
Nat Rev Cancer. 2019 Oct;19(10):568-586. (PMID: 31462760)
Br J Cancer. 2016 Apr 12;114(8):917-28. (PMID: 26954716)
Breast Cancer Res Treat. 2011 May;127(1):99-108. (PMID: 20556505)
Histopathology. 2018 Dec;73(6):887-896. (PMID: 29947077)
Breast Cancer Res. 2018 Mar 22;20(1):21. (PMID: 29566741)
J Exp Med. 2000 Oct 2;192(7):1027-34. (PMID: 11015443)
Breast Cancer Res Treat. 2019 Apr;174(2):387-399. (PMID: 30554343)
Breast Cancer Res Treat. 2017 Jul;164(2):317-325. (PMID: 28451966)
Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3131-3135. (PMID: 30486600)
Ann Oncol. 2019 Mar 1;30(3):397-404. (PMID: 30475950)
Annu Rev Immunol. 2005;23:225-74. (PMID: 15771571)
Oncoimmunology. 2018 Sep 21;8(1):e1512942. (PMID: 30546951)
Oncol Rep. 2019 Feb;41(2):1293-1303. (PMID: 30483814)
Brief Funct Genomic Proteomic. 2009 May;8(3):174-83. (PMID: 19535508)
Clin Cancer Res. 2004 Aug 15;10(16):5361-6. (PMID: 15328173)
Clin Transl Oncol. 2016 May;18(5):497-506. (PMID: 26459255)
Tumour Biol. 2014 Apr;35(4):2871-82. (PMID: 24338768)
Cell Commun Signal. 2018 Sep 5;16(1):55. (PMID: 30185178)
Cancer Med. 2018 Oct;7(10):5066-5082. (PMID: 30240146)
Mol Med. 2015 Feb 05;20:559-68. (PMID: 25247291)
Breast Cancer Res. 2013;15(5):R91. (PMID: 24074261)
Eur J Immunol. 2006 Jan;36(1):190-8. (PMID: 16380958)
Arch Pathol Lab Med. 1985 Aug;109(8):716-21. (PMID: 3893381)
Leukemia. 2008 May;22(5):980-8. (PMID: 18288129)
Tissue Antigens. 2004 Sep;64(3):215-25. (PMID: 15304001)
J Exp Med. 2006 Jun 12;203(6):1419-25. (PMID: 16754721)
Curr Probl Cancer. 2019 Feb;43(1):18-26. (PMID: 29776595)
PLoS One. 2018 May 16;13(5):e0197162. (PMID: 29768462)
Breast Cancer Res. 2018 Jun 22;20(1):62. (PMID: 29929548)
Ann Oncol. 2019 Mar 1;30(3):405-411. (PMID: 30475947)
J Clin Pathol. 2015 Feb;68(2):93-9. (PMID: 25488926)
Int J Cancer. 2019 Dec 1;145(11):3140-3151. (PMID: 31020993)
Breast Cancer Res Treat. 2010 Jul;122(1):45-53. (PMID: 19701705)
Breast Cancer Res Treat. 2011 Jun;127(3):591-9. (PMID: 20623333)
Jpn J Cancer Res. 1997 Jun;88(6):590-9. (PMID: 9263537)
Cancer Microenviron. 2013 Aug;6(2):123-33. (PMID: 23242673)
Nature. 2012 Apr 18;486(7403):346-52. (PMID: 22522925)
J Biol Chem. 2003 Jun 6;278(23):20989-94. (PMID: 12644459)
معلومات مُعتمدة: 1158 Pathological Society of Great Britain and Ireland
فهرسة مساهمة: Keywords: LAIR-1; breast cancer; collagens; immune cell markers; prognosis
تواريخ الأحداث: Date Created: 20210105 Latest Revision: 20240805
رمز التحديث: 20240805
مُعرف محوري في PubMed: PMC7795350
DOI: 10.3390/cancers13010080
PMID: 33396670
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13010080